ArticleClinical and molecular hepatology2024

Atezolizumab and bevacizumab for hepatocellular carcinoma: How to approach salvage therapy for non-responders?: Editorial on "Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: A real-world study".

Naoshi NishidaPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.